• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雾化米力农对药物诱导的羔羊肺动脉高压的影响。

Effect of aerosolized milrinone during drug-induced pulmonary hypertension in lambs.

作者信息

Gelvez Javier, Fakioglu Harun, Olarte Jose L, Soliz Amed, Totapally Balagangadhar R, Torbati Dan

机构信息

Division of Critical Care Medicine, Miami Children's Hospital, 3100 SW 62nd Avenue, Miami, FL 33156-3009, USA.

出版信息

Pharmacol Res. 2004 Jul;50(1):87-91. doi: 10.1016/j.phrs.2003.12.005.

DOI:10.1016/j.phrs.2003.12.005
PMID:15082033
Abstract

We tested whether aerosolized milrinone in lambs selectively reduces drug-induced acute pulmonary hypertension without reducing the mean systemic blood pressure (MSBP). Seven, 2-3-week-old lambs were anesthetized (50 mg/kg ketamine), paralyzed (0.1 mg/kg vecuronium bromide) and mechanically ventilated. A femoral artery, pulmonary artery, and jugular vein were catheterized for continuous monitoring of MSBP, mean pulmonary artery pressure, periodic gas-exchange analyses, and determination of cardiac output by thermodilution technique. An Airlife Misty nebulizer was used in a dry state to establish a stable baseline of an inspired fraction of oxygen (FiO(2)) at 0.21. Acute pulmonary hypertension with hypoxemia was then induced by increasing the mean pulmonary artery pressure up to 30-35% of the MSBP using 2-6 microg/kg/min of Thromboxane A(2) mimetic (U-46619), intravenously. The lambs were then subjected to 15 min of saline nebulization without milrinone followed by 30 min saline nebulization with a relatively high concentration of milrinone (10 mg/ml, total dose of 40 mg). Aerosolized milrinone had no effect on systemic or pulmonary artery pressure during combined acute pulmonary hypertension and hypoxemia. We speculate that our nebulization procedures failed to deliver sufficient amount of milrinone for producing a detectable hemodynamic effect.

摘要

我们测试了雾化米力农对羔羊是否能选择性降低药物诱导的急性肺动脉高压而不降低平均体循环血压(MSBP)。七只2 - 3周龄的羔羊接受麻醉(50mg/kg氯胺酮)、麻痹(0.1mg/kg维库溴铵)并进行机械通气。将一根股动脉、肺动脉和颈静脉插管,用于连续监测MSBP、平均肺动脉压、定期气体交换分析以及通过热稀释技术测定心输出量。使用处于干燥状态的Airlife Misty雾化器在吸入氧分数(FiO(2))为0.21时建立稳定的基线。然后通过静脉注射2 - 6μg/kg/min的血栓素A(2)类似物(U - 46619)将平均肺动脉压升高至MSBP的30 - 35%来诱导伴有低氧血症的急性肺动脉高压。随后羔羊先接受15分钟无米力农的盐水雾化,接着接受30分钟较高浓度米力农(10mg/ml,总剂量40mg)的盐水雾化。在合并急性肺动脉高压和低氧血症期间,雾化米力农对体循环或肺动脉压没有影响。我们推测我们的雾化程序未能输送足够量的米力农以产生可检测到的血流动力学效应。

相似文献

1
Effect of aerosolized milrinone during drug-induced pulmonary hypertension in lambs.雾化米力农对药物诱导的羔羊肺动脉高压的影响。
Pharmacol Res. 2004 Jul;50(1):87-91. doi: 10.1016/j.phrs.2003.12.005.
2
Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension.雾化前列环素和米力农可改善实验性肺动脉高压新生羔羊的肺血流动力学。
J Appl Physiol (1985). 2010 Sep;109(3):677-84. doi: 10.1152/japplphysiol.01082.2009. Epub 2010 Jul 8.
3
Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.使用III型和V型磷酸二酯酶抑制剂:米力农和西地那非联合治疗在血栓素诱导的急性肺动脉高压期间是有效的。
Br J Anaesth. 2006 Mar;96(3):317-22. doi: 10.1093/bja/ael009. Epub 2006 Jan 27.
4
Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension.吸入一氧化氮与静脉注射米力农对实验性肺动脉高压的相加作用。
Crit Care Med. 2000 Mar;28(3):795-9. doi: 10.1097/00003246-200003000-00031.
5
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.可溶性鸟苷酸环化酶激活剂可逆转清醒羔羊的急性肺动脉高压,并增强其对吸入一氧化氮的肺血管舒张反应。
Circulation. 2004 Oct 12;110(15):2253-9. doi: 10.1161/01.CIR.0000144469.01521.8A. Epub 2004 Oct 4.
6
Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery.比较吸入性米力农和静脉注射米力农在二尖瓣手术合并肺动脉高压患者中的应用。
Adv Ther. 2009 Apr;26(4):462-8. doi: 10.1007/s12325-009-0019-4. Epub 2009 Apr 16.
7
Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.新型磷酸二酯酶V型抑制剂(UK 343 - 664)与米力农在猪急性肺动脉高压模型中的作用比较
Ann Thorac Surg. 2004 Oct;78(4):1433-7. doi: 10.1016/j.athoracsur.2004.04.039.
8
Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.替唑生坦是一种肠外联合内皮素受体拮抗剂,可使患有急慢性肺动脉高压的羔羊出现肺血管舒张。
Pediatr Crit Care Med. 2004 Nov;5(6):571-7. doi: 10.1097/01.PCC.0000137357.52609.F0.
9
Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates.在心脏移植候选患者中使用雾化吸入米力农进行选择性肺血管舒张。
Can J Anaesth. 2005 Dec;52(10):1076-82. doi: 10.1007/BF03021608.
10
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.磷酸二酯酶抑制剂的共雾化显著增强了实验性肺动脉高压中对吸入伊洛前列素的肺血管舒张反应。维持肺选择性。
Am J Respir Crit Care Med. 2001 Nov 1;164(9):1694-700. doi: 10.1164/ajrccm.164.9.2105060.

引用本文的文献

1
A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.体外循环后肺动脉高压患者吸入米力农与伊洛前列素的回顾性比较
Heart Vessels. 2017 Dec;32(12):1488-1497. doi: 10.1007/s00380-017-1023-2. Epub 2017 Jul 17.
2
A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients.一项针对高危心脏手术患者吸入米力农的多中心随机对照试验。
Can J Anaesth. 2016 Oct;63(10):1140-1153. doi: 10.1007/s12630-016-0709-8. Epub 2016 Jul 28.
3
Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes.
米力农可减轻低氧肺动脉平滑肌细胞中血栓素受体介导的高反应性。
Br J Pharmacol. 2011 Jul;163(6):1223-36. doi: 10.1111/j.1476-5381.2011.01306.x.
4
Arterial pulmonary hypertension in noncardiac intensive care unit.非心脏重症监护病房中的动脉性肺动脉高压
Vasc Health Risk Manag. 2008;4(5):1043-60. doi: 10.2147/vhrm.s3998.